Novo Nordisk's Ziltivekimab Fails to Reduce Cardiovascular Events in Phase 3 ZEUS Trial
The Danish pharmaceutical giant's investigational IL-6 inhibitor showed biological activity but no clinical benefit in patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation.
Trial Misses Primary Endpoint
Novo Nordisk A/S disclosed that ziltivekimab, an investigational monoclonal antibody targeting cardiovascular inflammation, failed to demonstrate a reduction in major adverse cardiovascular events (MACE) compared to placebo in the phase 3 ZEUS trial. The study enrolled over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers (6-K filing, 2026-07-31).
The trial produced a hazard ratio of 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no statistical difference between ziltivekimab and placebo in reducing the composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke (6-K filing, 2026-07-31).
Biological Activity Without Clinical Benefit
While ziltivekimab failed on the primary endpoint, the drug demonstrated its intended biological mechanism. The compound showed "target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP)" (6-K filing, 2026-07-31). However, this anti-inflammatory effect did not translate into reduced cardiovascular events.
Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, acknowledged the disconnect: "Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population" (6-K filing, 2026-07-31).
ZEUS was designed as a double-blind, placebo-controlled trial testing once-monthly subcutaneous injections of ziltivekimab 15 mg in patients with ASCVD, CKD, and hsCRP levels of 2 mg/L or higher (6-K filing, 2026-07-31).
Safety Profile and Ongoing Trials
Overall adverse events and serious adverse events were similar between treatment groups. However, consistent with IL-6 inhibition's known effects, "a higher proportion of people treated with ziltivekimab had serious infections compared to placebo," though no difference in all-cause mortality was observed (6-K filing, 2026-07-31).
Despite the ZEUS failure, Novo Nordisk plans to continue two additional cardiovascular outcomes trials: HERMES, studying ziltivekimab in heart failure patients, and ARTEMIS, evaluating the drug following acute heart attack. Both trials are expected to report results in the first half of 2027 (6-K filing, 2026-07-31).
Financial Impact
The company stated that "the outcome of ZEUS will not impact Novo Nordisk's previously communicated adjusted operating profit outlook for 2026 but will result in a non-cash impairment charge in Q3 2026" (6-K filing, 2026-07-31). Full trial results will be presented at an upcoming scientific meeting later this year.
Lange emphasized that the setback "does not change our strategic commitment to cardiovascular disease," adding that the study "provides important scientific evidence that will inform our ongoing cardiovascular research" (6-K filing, 2026-07-31).
MarginX data shows Novo Nordisk is scheduled to report second-quarter 2026 results on August 5, followed by an analyst and investor day on September 16. The $209 billion market-cap company, headquartered in Bagsværd, Denmark, trades at DKK 306.5.
This article was generated by MarginX from the 6-K filing on 2026-07-31. It is not investment advice.